Subacute myeloid leukemia: a clinical review.
The data on 31 patients who fit into the clinical spectrum of subacute myeloid leukemia have been reviewed. The majority of patients were male with a median age of 61 years. The interval from onset of symptoms to actual diagnosis was extremely variable, with a mean of 16 months and a median of six months. Most patients presented with anemia and thrombocytopenia, although the white blood cell count varied from striking leukopenia to marked leukocytosis. Examination of the bone marrow invariably revealed abnormalities of all cell lines with megaloblastoid erythrogenesis and dysplastic megakaryocytopoiesis. Although the white cell line showed prominence of immature forms, there was more maturation than is seen in acute myeloid leukemia. Survival from diagnosis was variable, from less than one month to greater than 68 months, with a median of only six months. Anemia and hepatosplenomegaly were prognosticators of a poor outlook; patients with hepatosplenomegaly in association with either leukocytosis or thrombocytopenia had a particularly poor outlook, with a median survival of only one and a half months. Approximately half the patients received chemotherapy with no demonstrated effect on survival.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001772:Blood Cell Count; D001854:Bone Marrow Cells; D006400:Hematocrit; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D007962:Leukocytes / Q000201:enzymology; D008875:Middle Aged; D009113:Muramidase / Q000097:blood; D011379:Prognosis; D013921:Thrombocytopenia / Q000097:blood
D000970:Antineoplastic Agents; D000469:Alkaline Phosphatase; D009113:Muramidase